doi: 10.1016/S0306-4522(96)00434-4 [DOI] [PubMed] [Google Scholar] 29.Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjholm
Beyond diabetes and obesity, GLP-1 drugs are approved or being studied for sleep apnea, and researchers are exploring possible benefits for heart disease, kidney disease, and substance use disorders
Dennoch kann es wie bei jedem Nahrungsergnzungsmittel vereinzelt zu Nebenwirkungen kommen, insbesondere bei berdosierung oder individueller Unvertrglichkeit
Final thoughts Combining cagrilintide with tirzepatide represents an experimental approach with theoretical weight loss potential of 20-30% but zero clinical data supporting safety or efficacy
To ensure a precise comparison, the team applied a target trial emulation method that closely mirrors randomized clinical trials using observational data